Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Icatibant (Firazyr) Peptide
Bradykinin B2 receptor antagonist for hereditary angioedema attacks.
What is Icatibant (Firazyr)?
Icatibant (Firazyr) is a bradykinin antagonist · immunology peptide studied for hereditary angioedema (acute attacks). Below is an educational overview of Icatibant (Firazyr) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Firazyr
Acute attacks of hereditary angioedema (HAE) in adults.
A self-injected pen used at the first sign of an HAE attack to block the swelling-causing receptor (bradykinin B2).
- •Injection-site reactions (redness, swelling, itching)
- •Fever
- •Dizziness
- •Headache
- •Laryngeal attacks still need ER care
- •Possible heart ischemia in patients with coronary disease
- •Unstable coronary artery disease (use with caution)
- •Children (off-label, talk to a specialist)
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Icatibant (Firazyr) Mechanism of Action
Synthetic decapeptide that competitively blocks the bradykinin B2 receptor, halting the vascular leak that drives HAE swelling attacks.
Icatibant (Firazyr) Research Areas & Benefits
Icatibant (Firazyr) Dosage & Common Research Protocols
30 mg SC; repeat every 6h if needed (max 3 doses/24h).
Protocols summarized for educational reference from published research. Not dosing guidance.
Icatibant (Firazyr) Studies & Cited Research
FAST-3 trial
Faster symptom relief vs placebo in HAE attacks.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Icatibant (Firazyr) Side Effects & Safety Considerations
- •FDA-approved.
- •Injection-site reactions very common.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.